• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胃癌中的 HIF:调控与治疗靶点

HIF in Gastric Cancer: Regulation and Therapeutic Target.

机构信息

Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Department of Oncology, Peking University Shenzhen Hospital, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen 518036, China.

Department of Pathology, Peking University Shenzhen Hospital, Shenzhen 518036, China.

出版信息

Molecules. 2022 Jul 31;27(15):4893. doi: 10.3390/molecules27154893.

DOI:10.3390/molecules27154893
PMID:35956843
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9370240/
Abstract

HIF means hypoxia-inducible factor gene family, and it could regulate various biological processes, including tumor development. In 2021, the FDA approved the new drug Welireg for targeting HIF-2a, and it is mainly used to treat von Hippel-Lindau syndrome, which demonstrated its good prospects in tumor therapy. As the fourth deadliest cancer worldwide, gastric cancer endangers the health of people all across the world. Currently, there are various treatment methods for patients with gastric cancer, but the five-year survival rate of patients with advanced gastric cancer is still not high. Therefore, here we reviewed the regulatory role and target role of HIF in gastric cancer, and provided some references for the treatment of gastric cancer.

摘要

HIF 是缺氧诱导因子基因家族的英文缩写,它可以调节多种生物过程,包括肿瘤的发生发展。2021 年,FDA 批准了针对 HIF-2a 的新药 Welireg,主要用于治疗 von Hippel-Lindau 综合征,这表明其在肿瘤治疗方面具有广阔的前景。胃癌是全球第四大致死癌症,危害着全世界人民的健康。目前,胃癌患者有多种治疗方法,但晚期胃癌患者的五年生存率仍然不高。因此,我们在这里综述了 HIF 在胃癌中的调控作用和靶点作用,为胃癌的治疗提供了一些参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c8/9370240/730027be2bb7/molecules-27-04893-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c8/9370240/33f92aa14fc4/molecules-27-04893-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c8/9370240/fbfa069fa864/molecules-27-04893-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c8/9370240/8a878533fed0/molecules-27-04893-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c8/9370240/babf2a4ab37d/molecules-27-04893-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c8/9370240/730027be2bb7/molecules-27-04893-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c8/9370240/33f92aa14fc4/molecules-27-04893-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c8/9370240/fbfa069fa864/molecules-27-04893-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c8/9370240/8a878533fed0/molecules-27-04893-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c8/9370240/babf2a4ab37d/molecules-27-04893-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5c8/9370240/730027be2bb7/molecules-27-04893-g005.jpg

相似文献

1
HIF in Gastric Cancer: Regulation and Therapeutic Target.胃癌中的 HIF:调控与治疗靶点
Molecules. 2022 Jul 31;27(15):4893. doi: 10.3390/molecules27154893.
2
Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.缺氧诱导因子(HIF)-1α与HIF-2α在响应缺氧、胰岛素样生长因子-I或冯·希佩尔-林道功能丧失时对HIF靶基因调控中的作用:对靶向HIF途径的启示
Cancer Res. 2006 Jun 15;66(12):6264-70. doi: 10.1158/0008-5472.CAN-05-2519.
3
Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells.胃上皮活性氧可防止胃癌细胞中缺氧诱导因子-1α的常氧降解。
Clin Cancer Res. 2003 Jan;9(1):433-40.
4
Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.缺氧诱导因子在人类肾癌中的表达:与血管生成及冯·希佩尔-林道基因突变的关系。
Cancer Res. 2002 May 15;62(10):2957-61.
5
Crocin inhibits the migration, invasion, and epithelial-mesenchymal transition of gastric cancer cells via miR-320/KLF5/HIF-1α signaling.藏红花酸通过 miR-320/KLF5/HIF-1α 信号通路抑制胃癌细胞的迁移、侵袭和上皮间质转化。
J Cell Physiol. 2019 Aug;234(10):17876-17885. doi: 10.1002/jcp.28418. Epub 2019 Mar 9.
6
Hypoxia-inducible factor-1alpha expression predicts the response to 5-fluorouracil-based adjuvant chemotherapy in advanced gastric cancer.缺氧诱导因子-1α表达可预测晚期胃癌对基于5-氟尿嘧啶的辅助化疗的反应。
Oncol Rep. 2009 Oct;22(4):693-9. doi: 10.3892/or_00000489.
7
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.在肾癌细胞中,因冯·希佩尔-林道肿瘤抑制基因功能缺失,缺氧诱导因子HIF-1α和HIF-2α在常氧条件下上调。
Oncogene. 2000 Nov 16;19(48):5435-43. doi: 10.1038/sj.onc.1203938.
8
Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.缺氧诱导因子1α、缺氧诱导因子2α及冯·希佩尔-林道蛋白在上皮性卵巢肿瘤中的表达及冯·希佩尔-林道基因的等位基因缺失:缺氧诱导因子1α的核表达是卵巢癌的独立预后因素。
Hum Pathol. 2007 Sep;38(9):1310-20. doi: 10.1016/j.humpath.2007.02.010. Epub 2007 Jun 6.
9
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.硒通过脯氨酰羟化酶 2 依赖性和 von Hippel-Lindau 非依赖性降解,抑制肾透明细胞癌细胞中低氧诱导因子 1 和 2α,从而抑制肿瘤生长。
BMC Cancer. 2012 Jul 17;12:293. doi: 10.1186/1471-2407-12-293.
10
Altered expression of hypoxia-inducible factor-1α (HIF-1α) and its regulatory genes in gastric cancer tissues.缺氧诱导因子-1α(HIF-1α)及其调控基因在胃癌组织中的表达改变
PLoS One. 2014 Jun 13;9(6):e99835. doi: 10.1371/journal.pone.0099835. eCollection 2014.

引用本文的文献

1
A Novel Hypoxia-Immune Signature for Gastric Cancer Prognosis and Immunotherapy: Insights from Bulk and Single-Cell RNA-Seq.一种用于胃癌预后和免疫治疗的新型缺氧-免疫特征:来自批量和单细胞RNA测序的见解
Curr Issues Mol Biol. 2025 Jul 16;47(7):552. doi: 10.3390/cimb47070552.
2
VASN drives gastric tumorigenesis via activation of the COL4A1/PI3K/AKT axis during Helicobacter pylori infection.在幽门螺杆菌感染期间,VASN通过激活COL4A1/PI3K/AKT轴驱动胃癌发生。
Br J Cancer. 2025 Jun 23. doi: 10.1038/s41416-025-03081-7.
3
Deciphering the dual role of autophagy in gastric cancer and gastroesophageal junction cancer: from tumor suppression to cancer progression.

本文引用的文献

1
Structural Basis for Control of Methylation Extent in Polyketide Synthase Metal-Dependent -Methyltransferases.聚酮合酶金属依赖性 -甲基转移酶中甲基化程度控制的结构基础。
ACS Chem Biol. 2022 Aug 19;17(8):2088-2098. doi: 10.1021/acschembio.2c00085. Epub 2022 May 20.
2
Metabolic diversity drives cancer cell invasion.代谢多样性驱动癌细胞侵袭。
Nature. 2022 May;605(7911):627-628. doi: 10.1038/d41586-022-01301-1.
3
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial.阿哌沙班与经导管主动脉瓣置换术后标准治疗的比较:ATLANTIS 试验。
解读自噬在胃癌和胃食管交界癌中的双重作用:从肿瘤抑制到癌症进展。
Discov Oncol. 2025 Jun 5;16(1):1013. doi: 10.1007/s12672-025-02802-x.
4
Research progress on the therapeutic effects of effective components of traditional Chinese medicine in the treatment of gastric cancer precursors through modulation of multiple signaling pathways.中药有效成分通过调控多条信号通路治疗胃癌前体病变的研究进展
Front Oncol. 2025 May 19;15:1555274. doi: 10.3389/fonc.2025.1555274. eCollection 2025.
5
Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient-Derived Tissue Laden Tissue-Specific Bioink.通过使用患者来源的富含组织的组织特异性生物墨水的3D生物打印胃癌模型预测患者的药物反应。
Adv Sci (Weinh). 2025 Mar;12(10):e2411769. doi: 10.1002/advs.202411769. Epub 2025 Jan 2.
6
Matching traditional Chinese medicine and western medicine-based research: Advanced nutraceutical development for proactive gastric cancer prevention.中西医结合研究:用于积极预防胃癌的先进营养保健品开发。
World J Gastrointest Oncol. 2024 Sep 15;16(9):3798-3819. doi: 10.4251/wjgo.v16.i9.3798.
7
The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics.间充质干细胞在癌症中的作用及其在癌症治疗中的应用前景。
MedComm (2020). 2024 Jul 28;5(8):e663. doi: 10.1002/mco2.663. eCollection 2024 Aug.
8
Adjuvant Properties of Caffeic Acid in Cancer Treatment.咖啡酸在癌症治疗中的辅助特性。
Int J Mol Sci. 2024 Jul 11;25(14):7631. doi: 10.3390/ijms25147631.
9
HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma.缺氧诱导因子-1(HIF-1)失活使缺氧诱导因子-2(HIF-2)能够驱动侵袭性髓母细胞瘤形式的缺氧适应。
Cell Death Discov. 2024 Jul 24;10(1):338. doi: 10.1038/s41420-024-02100-5.
10
Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer.癌症中缺氧诱导因子的治疗靶向。
Int J Mol Sci. 2024 Feb 8;25(4):2060. doi: 10.3390/ijms25042060.
Eur Heart J. 2022 Aug 1;43(29):2783-2797. doi: 10.1093/eurheartj/ehac242.
4
Structure-function analysis of the AMPK activator SC4 and identification of a potent pan AMPK activator.结构-功能分析 AMPK 激活剂 SC4 并鉴定出一种有效的泛 AMPK 激活剂。
Biochem J. 2022 Jun 17;479(11):1181-1204. doi: 10.1042/BCJ20220067.
5
Penetrating-peptide-mediated non-invasive Axitinib delivery for anti-neovascularisation.穿透肽介导的非侵入性阿昔替尼递药用于抗血管生成。
J Control Release. 2022 Jul;347:449-459. doi: 10.1016/j.jconrel.2022.05.009. Epub 2022 May 19.
6
PLGA sustained-release microspheres loaded with an insoluble small-molecule drug: microfluidic-based preparation, optimization, characterization, and evaluation and .载不溶性小分子药物的 PLGA 缓释微球:基于微流控的制备、优化、表征和评价
Drug Deliv. 2022 Dec;29(1):1437-1446. doi: 10.1080/10717544.2022.2072413.
7
Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study.接受透析治疗的非瓣膜性心房颤动患者的阿哌沙班剂量模式与华法林:一项回顾性队列研究。
Am J Kidney Dis. 2022 Nov;80(5):569-579.e1. doi: 10.1053/j.ajkd.2022.03.007. Epub 2022 Apr 22.
8
Metabolism and Vascular Retinopathies: Current Perspectives and Future Directions.代谢与视网膜血管病变:当前观点与未来方向
Diagnostics (Basel). 2022 Apr 5;12(4):903. doi: 10.3390/diagnostics12040903.
9
Novel factor XIa inhibitor reduces bleeding compared with apixaban in atrial fibrillation.与阿哌沙班相比,新型凝血因子XIa抑制剂可减少房颤患者的出血情况。
Nat Rev Cardiol. 2022 Jun;19(6):350. doi: 10.1038/s41569-022-00714-9.
10
The role of hypoxia-inducible factors in cardiovascular diseases.缺氧诱导因子在心血管疾病中的作用。
Pharmacol Ther. 2022 Oct;238:108186. doi: 10.1016/j.pharmthera.2022.108186. Epub 2022 Apr 9.